Shot chasers: big pharma’s covid-19 boost

Sobre este episódio

<p>The pandemic has caused a shift in how drug firms are viewed: their capacity for big-money innovation will give them immunity in the crisis. Widespread homeworking will have broad consequences, from commercial-property values to urban demographics. And a seemingly innocuous Hong Kong history exam is a window into the territory’s increasingly fraught politics. </p><p>For full access to print, digital and audio editions of <em>The Economist</em>, subscribe here <a href="http://www.economist.com/radiooffer" rel="noopener noreferrer" target="_blank">www.economist.com/radiooffer</a></p> <hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>